Abstracts tagged "Antibodies"

Abstract Number: L02 • 2019 ACR/ARP Annual Meeting
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Naizhuo Zhao ¹, Audrey Smargiassi ², Marianne Hatzopoulou ³, Ines Colmegna ⁴, Marie Hudson ⁵, Marvin Fritzler ⁶, Philip Awadalla ⁷ and Sasha Bernatsky⁸, ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²University of Montreal, Montreal, Canada, ³University of Toronto, Toronto, Canada, ⁴McGill University Health Center, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, Canada, ⁶Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁷Ontario Institute for Cancer Research, Toronto, Canada, ⁸Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Studies of associations between industrial air emissions and rheumatic disease, or diseases-related serological biomarkers, are few. Moreover, previous evaluations typically studied individual (not mixed)…
Abstract Number: 964 • 2019 ACR/ARP Annual Meeting
Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Jennifer Young-Glazer¹, Erin Wilfong ², Peggy Kendall ¹, Rachel Bonami ¹ and Leslie Crofford ², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases traditionally classified as dermatomyositis or polymyositis, but these disorders are increasingly defined by the presence of…
Abstract Number: 1274 • 2019 ACR/ARP Annual Meeting
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Sho Sasaki¹, Akira Ishii ², Mai Sugiyama ², Yuto Izumi ², Yoko Nakagome ², Kazuki Hirano ³, Takayoshi Kurabayashi ¹, Shinichi Nogi ⁴, Noriko Sasaki ², Chiho Yamada ² and Shinji Sato ⁵, ¹Tokai Universitiy School of Medicine, Isehara, Japan, ²Tokai University School of Medicine, Isehara, Japan, ³Tokai University School of Medicine, Isehara, ⁴National Hospital Organization Sagamihara Hospital, Sagamihara, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Yokohama, Japan
Background/Purpose: Anti-KS antibody, an anti-aminoacyl tRNA synthetase (ARS) antibody, is found mainly in patients with interstitial lung disease (ILD) accompanied by polymyositis/dermatomyositis (PM/DM). Although anti-KS…
Abstract Number: 1288 • 2019 ACR/ARP Annual Meeting
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Fergus To¹, Clara Ventín Rodríguez ², Shuayb Elkhalifa ³, James Lilleker ⁴ and Hector Chinoy ⁴, ¹University of British Columbia, Vancouver, Canada, ²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³(3) Department of Immunology, Salford Royal NHS Foundation, Salford, United Kingdom, ⁴University of Manchester, Manchester, United Kingdom
Background/Purpose: To evaluate the real-world accuracy of a line blot immunoassay (LIA) for myositis-specific (MSA) and myositis-associated (MSA) autoantibody testing in patients at a tertiary…
Abstract Number: 109 • 2019 ACR/ARP Annual Meeting
Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis
Yan Li ¹, Jeffrey H. Ruth ², Stephanie Rasmussen ³, Kalana S. Athukorala ², Daniel P. Weber ², M. Asif Amin ², Phillip Campbell ³, Nora Singer ⁴, David Fox⁵ and Feng Lin ¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁴The MetroHealth System -Case Western Reserve University School of Medicine, Cleveland, OH, ⁵Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI
Background/Purpose: CD6, an important regulator of T cell function, interacts with the ligands CD166 and CD318. We previously examined CD318 expression on synovial tissues (STs)…
Abstract Number: 814 • 2018 ACR/ARHP Annual Meeting
NON Diffuse SSc, Peripheral Neuropathy, Concomitant Sjogren Syndrome and ANTI-RNA Polymerase III Represent Risk Factors for the Higher Frequency of Cancer in a Large Single Cohort of Patients with Systemic Sclerosis
Ana Paula Luppino-Assad¹, Adriana Bortoluzzo², Henrique Carriço da Silva³, Danieli Andrade⁴ and Percival Sampaio-Barros⁴, ¹Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., sao paulo, Brazil, ²c Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brasil, sao paulo, Brazil, ³Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., SAO PAULO, Brazil, ⁴Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: A higher prevalence of cancer has been described in patients with systemic sclerosis (SSc), but the magnitude of this risk and the type of…
Abstract Number: 999 • 2018 ACR/ARHP Annual Meeting
Development of an Affimab Engineered to Simultaneously Target IL-6 and Tnfα for Therapeutic Use in Rheumatoid Arthritis
Kyu-Tae Kim, Jong-Seo Lee and Bong-Kook Ko, AbClon Inc., Seoul, Korea, Republic of (South)
Background/Purpose: Antibodies may be functionalized using Affibody® molecules to create bispecific AffiMabs. We used protein engineering to develop single-construct biologics suitable for blocking inflammation driven…
Abstract Number: 1223 • 2018 ACR/ARHP Annual Meeting
Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis
Caitlyn L. Holmes¹, Chloe Peyton², Amy Bier³, Tobias Donlon², Christie M. Bartels⁴ and Miriam A. Shelef^5,6, ¹University of Wisconsin - Madison, Madison, WI, ²University of Minnesota Medical School, Minneapolis, MN, ³Stritch School of Medicine of Loyola University Chicago, Chicago, IL, ⁴Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ⁵Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, ⁶William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response…
Abstract Number: 1310 • 2018 ACR/ARHP Annual Meeting
Diagnostic Utility of Myositis Antibodies in Patients with Interstitial Lung Disease and Suspected Underlying Connective Tissue Disease
Verónica Wolff¹, Juan Maya², Carolina Cuéllar³, Matías Florenzano¹, Alexis Peralta⁴ and Viviana Balboa⁴, ¹Rheumatic Lung diseases Unit, Instituto Nacional del Tórax, Santiago, Chile, ²Rheumatology Unit, Hospital del Salvador. Facultad de Medicina. Universidad de Chile, Santiago, Chile, ³Rheumatology Section, Hospital del Salvador, Universidad de Chile, SANTIAGO, Chile, ⁴Laboratorio Inmunología, Hospital Del Salvador, SANTIAGO, Chile
Background/Purpose: Interstitial Lung Disease (ILD) is a common manifestation of Connective Tissue Diseases (CTD), mainly Systemic sclerosis (SSc), Rheumatoid Arthritis and Idiopathic Inflammatory Myositis (IIM)…
Abstract Number: 1343 • 2018 ACR/ARHP Annual Meeting
A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Yuji Hosono^1,2, Ran Nakashima¹, Koji Kitagori¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Many kinds of autoantibodies are detected in idiopathic inflammatory myopathy (IIM) patients. Some of them are useful to diagnose, predict the clinical course, and…
Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Yuji Hosono¹, Iago Pinal-Fernandez¹, Katherine Pak¹, Jemima Albayda², Eleni Tiniakou³, Julie J. Paik⁴, Christopher A. Mecoli⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶ and Andrew Mammen^1,7, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
Abstract Number: 1551 • 2018 ACR/ARHP Annual Meeting
Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases
Johanna Gehin¹, Guro Løvik Goll², Silje Watterdal Syversen², David J Warren¹, Joseph Sexton³, Eldri Kvein Strand⁴, Tore Kvien⁵, Elisabeth Lie² and Nils Bolstad⁶, ¹Department of Medical Biochemistry, OUS-Radiumhospitalet, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Lillehammer Revmatismesykehus, Lillehammer, Norway, ⁵NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁶Department of Medical Biochemistry,, OUS-Radiumhospitalet, Oslo, Norway
Background/Purpose: Anti-drug antibodies (ADAb) to biological drugs predispose patients (pts) to low drug levels and lack of treatment response. For certolizumab pegol (CP) knowledge about…
Abstract Number: 1741 • 2018 ACR/ARHP Annual Meeting
Disease Duration and Autoantibodies Predict Distinct Skin Score Trajectories in Diffuse Cutaneous Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Voon H. Ong³ and Christopher P. Denton⁴, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, University College London, London, United Kingdom, ⁴University College London, London, United Kingdom
Background/Purpose: Although severity of skin involvement and change in skin thickness over time vary substantially between patients with diffuse cutaneous systemic sclerosis (dcSSc), for the…
Abstract Number: 1742 • 2018 ACR/ARHP Annual Meeting
Disease-Specific Autoantibodies Associate with Remarkably Different Risk of Development of Significant Lung Fibrosis in Systemic Sclerosis
Svetlana I. Nihtyanova¹, Alper Sari², Anna Leslie³, Voon H. Ong⁴ and Christopher P. Denton⁵, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁴Division of Medicine, University College London, London, United Kingdom, ⁵University College London, London, United Kingdom
Background/Purpose: Pulmonary fibrosis (PF) is a leading cause of disease-related death in SSc patients. Some studies suggest that the timing of PF development differs between…
Abstract Number: 1898 • 2018 ACR/ARHP Annual Meeting
Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach
Luis F. Perez-Garcia^1,2, Irving O. Estevez-Garcia³, Ricardo Marquez-Velasco³, Pedro Iturralde⁴, Luis H. Silveira⁵ and Luis M. Amezcua-Guerra^2,6,7, ¹Rheumatology, Erasmus MC, Rotterdam, Netherlands, ²Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ³Immunology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁴Cardiology - Electrophysiology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁵Rheumatology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City DF, Mexico, ⁶Cardiovascular Research Laboratory, Unidad de Investigacion Traslacional, Universidad Nacional Autonoma de Mexico/Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, ⁷Department of Health Care, Universidad Autonoma Metropolitana, Xochimilco, Mexico City, Mexico
Background/Purpose: Long QT syndrome (LQTS) is an abnormal QT corrected (QTc) interval prolongation, strongly associated with increased risk of sudden death. Studies have associated LQTS…

1
2
3
…
9
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].